Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.3947/ic.2020.52.3.410 http://scihub22266oqcxt.onion/10.3947/ic.2020.52.3.410 32342677!7533212!32342677     free     free     free       Infect+Chemother 2020 ; 52 (3): 410-414 Nephropedia Template TP {{tp|p=32342677|t=2020. Severe Thrombocytopenia in a Patient with COVID-19 |pdf=|usr=}}{{32342677}} gab.com Text Severe Thrombocytopenia in a Patient with COVID-19 JO: Infect Chemother http://www.kidney.de/pget.php?&tw=1&pmid=32342677 #FOAvip Coronavirus disease 2019 (COVID-19) outbreak is spreading rapidly all over the world, being a major threat to public health. Since clinical feature of COVID-19 has not been fully evaluated yet, empirical antibacterial agents are frequently combined for the treatment of COVID-19 in addition to antiviral agents, concerning co-existing bacterial pathogens. We experienced a case of severe thrombocytopenia with epistaxis and petechiae, while treating a COVID-19 patient with ceftriaxone, levofloxacin, and lopinavir/ritonavir. The platelet count decreased to 2,000/mm(3) and recovered after discontinuation of the three suspected drugs. In treating a potentially fatal emerging infectious disease, empirical and/or experimental approach would be unavoidable. However, the present case suggests that the possibility of adverse effects caused by polypharmacy should also be carefully considered. Twit Text FOAVip Severe Thrombocytopenia in a Patient with COVID-19 ????Infect Chemother http://www.kidney.de/pget.php?&tw=1&pmid=32342677 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32342677 #FOAvip English Wikipedia <ref>{{Cite pmid|32342677}}</ref> Severe Thrombocytopenia in a Patient with COVID-19 #MMPMID32342677 Nham E; Ko JH; Jeong BH; Huh K; Cho SY; Kang CI; Chung DR; Peck KR Infect Chemother 2020[Sep]; 52 (3): 410-414 PMID32342677show ga Coronavirus disease 2019 (COVID-19) outbreak is spreading rapidly all over the world, being a major threat to public health. Since clinical feature of COVID-19 has not been fully evaluated yet, empirical antibacterial agents are frequently combined for the treatment of COVID-19 in addition to antiviral agents, concerning co-existing bacterial pathogens. We experienced a case of severe thrombocytopenia with epistaxis and petechiae, while treating a COVID-19 patient with ceftriaxone, levofloxacin, and lopinavir/ritonavir. The platelet count decreased to 2,000/mm(3) and recovered after discontinuation of the three suspected drugs. In treating a potentially fatal emerging infectious disease, empirical and/or experimental approach would be unavoidable. However, the present case suggests that the possibility of adverse effects caused by polypharmacy should also be carefully considered. ?Severe Thrombocytopenia in a Patient with COVID-19 (epmc).pdf DeepDyve Pubget Overpricing